Biotech | October 31, 2023
Aragen setting up a US$ 30 million bio-manufacturing site in Bengaluru
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
The company expects that this development could improve the strength of its application to the FDA for new drug approval
ASMD is highly variable and the age of onset, specific symptoms and severity of the disorder can vary dramatically from one person to another
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Pant delivers keynote address at National Conclave on “Augmented Zoonotic Diseases Surveillance at Human – Wildlife Interface”
Seamless transition from preclinical to first-in-human trials with EUDRACAP platform technology
Prateek has more than 23 years of rich experience in Human Resource
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Animations, colors, and shapes help to improve poor situational awareness, which is responsible for 81.5% of anesthesia-related errors
Subscribe To Our Newsletter & Stay Updated
